secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivos Therapeutics, Inc. (VVOS)
CIK:        0001716166
Form:       8-K
Filed at:   2026-07-07T21:29:42+00:00
Accession:  0001493152-26-032387
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 5.03, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivos Therapeutics raises ~$2.1M in PIPE of convertible preferred and warrants
------------------------------------------------------------------------------

- Sold 3,608,496 units at $0.582/unit; each unit: one Series A Convertible Preferred (stated value $0.456) and one warrant (exercise $0.456, 5-year term).
- Gross proceeds ~$2.1M; $1M cash, $1M from conversion of bridge note; net proceeds for working capital.
- CEO R. Kirk Huntsman indirectly invested $50k via V-Co 4, an affiliate holding >9.99% of common stock.
- Warrants immediately exercisable; beneficial ownership limits: 19.99% for V-Co 4, 9.99% (or 4.99%) for Bigger Capital.
- Company must file resale registration statement within 45 days; Rights contingent on SEC effectiveness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226032387/0001493152-26-032387-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1716166/000149315226032387/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-032387

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer